- About Glen
Glen Ernst, M.S., joined the Drug Discovery Division at the Lieber Institute in May 2011. His current work involves applying medicinal chemistry principles and organic chemistry synthetic skills to generate potential target compounds for drug discovery across various targets of interest. Prior to joining the Lieber Institute, Glen worked in Medicinal Chemistry for over 20 years at AstraZeneca Pharmaceuticals, and was as a Principal Scientist and Project Chemistry Leader at the end of his tenure there. Glen’s work was primarily focused on drug discovery opposite several Central Nervous System disorders, including schizophrenia, depression, anxiety and migraine. His contributions led to the discovery of several new chemical entities which entered drug development. While at AstraZeneca, Glen was a co-recipient of the AstraZeneca Breakthrough Award for organic synthetic contributions to a schizophrenia project, and served on global committees within the AstraZeneca organization as his site’s representative.
LIBD Speaker Series: Eli A. Stahl, Ph.D.
Parsing the hits in neuropsych disorders: pathways, networks and transcriptomes. Eli A. Stahl, Ph.D. Assistant Professor Genetics and Genomic Sciences, Psychiatry Icahn School of Medicine at Mount Sinai When: November 28 3:00pm-4:00pm Where: The Lieber Institute for Brain Development Rangos […]